S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
"Prepare for Five Years of Famine" (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
How to Get ANOTHER 80% Off the Best Cryptos (Ad)pixel
NYSE:EVH

Evolent Health - EVH Stock Forecast, Price & News

$35.68
+0.53 (+1.51%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.53
$35.83
50-Day Range
$26.71
$36.50
52-Week Range
$21.36
$39.00
Volume
972,034 shs
Average Volume
778,104 shs
Market Capitalization
$3.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.38

Evolent Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.0% Upside
$46.38 Price Target
Short Interest
Bearish
9.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Evolent Health in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.01) to $0.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Computer And Technology Sector

284th out of 653 stocks

Management Services Industry

1st out of 7 stocks

EVH stock logo

About Evolent Health (NYSE:EVH) Stock

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

Evolent Health Stock Down 0.8 %

Evolent Health stock traded down $0.29 during mid-day trading on Wednesday, reaching $34.86. The stock had a trading volume of 7,936 shares, compared to its average volume of 776,798. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.23 and a current ratio of 1.23. Evolent Health has a fifty-two week low of $21.36 and a fifty-two week high of $39.00. The stock's 50-day simple moving average is $31.52 and its 200-day simple moving average is $29.09. The firm has a market capitalization of $3.19 billion, a PE ratio of -109.84 and a beta of 1.86.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Cowen boosted their target price on Evolent Health to $52.00 in a research report on Monday, July 25th. Cowen boosted their target price on Evolent Health from $48.00 to $50.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 21st. Canaccord Genuity Group boosted their target price on Evolent Health from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, August 4th. Piper Sandler boosted their price objective on Evolent Health from $35.00 to $40.00 and gave the company an "overweight" rating in a research report on Wednesday, August 3rd. Finally, BTIG Research boosted their price objective on Evolent Health from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, August 3rd. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $46.78.

Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

EVH Stock News Headlines

Evolent Health (NYSE:EVH) Price Target Raised to $50.00
What 6 Analyst Ratings Have To Say About Evolent Health
Why Evolent Health Was Such a Healthy Stock Today
Evolent Health Announces Second Quarter 2022 Results
Evolent Health's Earnings: A Preview
Evolent Health (NYSE:EVH) Trading 5.4% Higher
See More Headlines
Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

EVH Company Calendar

Last Earnings
11/03/2021
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
N/A
Employees
3,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.38
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+30.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-37,600,000.00
Pretax Margin
-1.72%

Debt

Sales & Book Value

Annual Sales
$907.96 million
Cash Flow
$0.85 per share
Book Value
$7.77 per share

Miscellaneous

Free Float
87,748,000
Market Cap
$3.27 billion
Optionable
Optionable
Beta
1.86

Key Executives














EVH Stock - Frequently Asked Questions

Should I buy or sell Evolent Health stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.
View EVH analyst ratings
or view top-rated stocks.

What is Evolent Health's stock price forecast for 2022?

8 equities research analysts have issued 12 month price objectives for Evolent Health's stock. Their EVH share price forecasts range from $37.00 to $55.00. On average, they predict the company's share price to reach $46.38 in the next year. This suggests a possible upside of 31.8% from the stock's current price.
View analysts price targets for EVH
or view top-rated stocks among Wall Street analysts.

How have EVH shares performed in 2022?

Evolent Health's stock was trading at $27.67 at the start of the year. Since then, EVH shares have increased by 27.1% and is now trading at $35.18.
View the best growth stocks for 2022 here
.

When is Evolent Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EVH earnings forecast
.

How were Evolent Health's earnings last quarter?

Evolent Health, Inc. (NYSE:EVH) posted its quarterly earnings results on Wednesday, November, 3rd. The technology company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.05. The technology company had revenue of $222.47 million for the quarter, compared to the consensus estimate of $226.18 million. Evolent Health had a negative net margin of 2.63% and a positive trailing twelve-month return on equity of 0.41%. During the same quarter in the prior year, the firm earned ($0.07) EPS.

What guidance has Evolent Health issued on next quarter's earnings?

Evolent Health issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Seth Blackley's approval rating as Evolent Health's CEO?

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolent Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

When did Evolent Health IPO?

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is Evolent Health's stock symbol?

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Who are Evolent Health's major shareholders?

Evolent Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Loomis Sayles & Co. L P (2.74%), Victory Capital Management Inc. (0.50%), Lisanti Capital Growth LLC (0.31%), Swiss National Bank (0.20%), Mckinley Capital Management LLC Delaware (0.13%) and Truist Financial Corp (0.12%). Insiders that own company stock include Cheryl Scott, Doug S Aron, Frank J Williams, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends
.

How do I buy shares of Evolent Health?

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolent Health's stock price today?

One share of EVH stock can currently be purchased for approximately $35.18.

How much money does Evolent Health make?

Evolent Health (NYSE:EVH) has a market capitalization of $3.22 billion and generates $907.96 million in revenue each year. The technology company earns $-37,600,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does Evolent Health have?

The company employs 3,500 workers across the globe.

How can I contact Evolent Health?

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The official website for the company is www.evolenthealth.com. The technology company can be reached via phone at (571) 389-6000, via email at investorrelations@evolenthealth.com, or via fax at 571-389-6001.

This page (NYSE:EVH) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.